Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 1×
“8) (52) to human reference genome (hg19) along with the gene annotation data downloaded from Illumina’s iGenomes (http://support.”
MethodMass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 2×
“As peptides eluted they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).”
MethodNGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 7×
“In many cases, ubiquitin is added to substrates by cullinRING ligases (CRLs), which are multisubunit ubiquitin ligases (23).”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“This is the same mechanism by which the plant hormone auxin acts like “molecular glue” to enhance an interaction between the E3 ubiquitin ligase receptor TIR1 and its substrates (43).”
Background
Cited by
Items 301–400 of 786
Structural insights into DDA1 function as a core component of the CRL4-DDB1 ubiquitin ligase
Shabek, N., Ruble, J., Waston, C. J., Garbutt, K. C., Hinds, T. R., Li, T., & Zheng, N. (2018) · Cell Discovery · doi:10.1038/s41421-018-0064-8 · Cited by 31
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 31
Targeting RNA-binding proteins in acute and chronic leukemia
Elcheva, I. A., & Spiegelman, V. S. (2020) · Leukemia · doi:10.1038/s41375-020-01066-4 · Cited by 39
The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
Coll-Martínez, B., Delgado, A., & Crosas, B. (2020) · Molecules · doi:10.3390/molecules25245956 · Cited by 28
T herapeutic targeting of chromatin: status and opportunities
Siklos, M. I., & Kubicek, S. (2021) · FEBS Journal · doi:10.1111/febs.15966 · Cited by 29
DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance
Zhou, N., Choi, J., Grothusen, G. P., Kim, B., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A. A., Beer, T., et al. (2023) · Blood · doi:10.1182/blood.2022018752 · Cited by 29
Feng, Y., Hu, X., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00638-1 · Cited by 30
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 32
Reprogramming of the epigenome in neurodevelopmental disorders
Wilson, K., Porter, E. G. P., & Garcia, B. A. (2021) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2021.1979457 · Cited by 27
Recent advances in induced proximity modalities
Ng, C. S. C., & Banik, S. M. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102107 · Cited by 27
Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases
Diaz, S., Wang, K., Sjögren, B., & Liu, X. (2022) · Biomolecules · doi:10.3390/biom12030416 · Cited by 27
Targeted protein degradation as an antiviral approach
Chakravarty, A., & Yang, P. L. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105480 · Cited by 29
Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex
Zhang, Z., Li, Y., Yang, J., Li, J., Lin, X., Liu, T., Yang, S., Lin, J., Xue, S., Yu, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50642-0 · Cited by 30
Shaik, S., Gayam, P. K. R., Chaudhary, M., Singh, G., & Pai, A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107868 · Cited by 27
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases
Blaquière, N., Villemure, E., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01451 · Cited by 26
Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 31
Lü, J., Jiang, H., Li, D., Chen, T., Wang, Y., Pu, Z., & Xu, G. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00437 · Cited by 27
Sun, J., Gu, M., Peng, L., Guo, J., Chen, P., Wen, Y., Fang, F., Chen, X., Liu, T., Chen, Y., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c11003 · Cited by 27
Probing ubiquitin and SUMO conjugation and deconjugation
Ovaa, H., & Vertegaal, A. C. O. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170086 · Cited by 26
Discovering new biology with drug-resistance alleles
Freedy, A. M., & Liau, B. B. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00865-9 · Cited by 25
Dias, M. H., Liudkovska, V., Navarro, J. M., Giebel, L., Champagne, J., Papagianni, C., Bleijerveld, O. B., Velds, A., Agami, R., Bernards, R., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00128-3 · Cited by 26
Exploiting E3 ligases for lung cancer therapy: The promise of DCAF-PROTACs
Hussain, M. S., Eltaib, L., Rana, A. J., Maqbool, M., Ashique, S., Alanazi, M. N., Khan, Y., & Agrawal, M. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156001 · Cited by 24
The von Hippel–Lindau Tumor Suppressor Protein
Kaelin, W. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050527 · Cited by 24
Riching, K. M., Vasta, J. D., Hughes, S. J., Zoppi, V., Maniaci, C., Testa, A., Urh, M., Ciulli, A., & Daniels, D. L. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100009 · Cited by 29
Controlled poly(olefin)s via decarboxylation of poly(acrylic acid)
Chapman, R., Melodia, D., Qu, J., & Stenzel, M. H. (2017) · Polymer Chemistry · doi:10.1039/c7py01466j · Cited by 24
Ye, X., Wei, X., Liao, J., Chen, P., Li, X., Chen, Y., Yang, Y., Zhao, Q., Sun, H., Pan, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.617190 · Cited by 27
RBM39 Alters Phosphorylation of c-Jun and Binds to Viral RNA to Promote PRRSV Proliferation
Song, Y., Guo, Y., Li, X., Sun, R., Zhu, M., Shi, J., Tan, Z., Zhang, L., & Huang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.664417 · Cited by 24
Elaboration of molecular glues that target TRIM21 into TRIMTACs that degrade protein aggregates
de Gialluly, M. A. S., Allen, A. R., Hayes, E. H., Zhuang, P., Goldfarb, R. B., Farrar, A. N., Federov, Y., & Adams, D. (2025) · Nature Communications · doi:10.1038/s41467-025-61818-7 · Cited by 25
Identification of a small molecule splicing inhibitor targeting UHM domains
Kobayashi, A., Clément, M., Craveur, P., Hage, K. E., Salone, J. D. M., Bollot, G., Pastré, D., & Maucuer, A. (2021) · FEBS Journal · doi:10.1111/febs.16199 · Cited by 25
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 24
Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway
Zhang, X., Yang, L., Liu, X., Nie, Z.-Y., Liu, M., Wang, T., Lu, Y., Pan, Y., Zhan, Y., Wang, Z., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119607 · Cited by 36
Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues
Hautin, M., Mornet, C., Chauveau, A., Bernard, D. G., Corcos, L., & Lippert, É. (2020) · Cancers · doi:10.3390/cancers12082216 · Cited by 23
Lucas, S. C. C., Ahmed, A., Ashraf, S. N., Argyrou, A., Bauer, M. R., Donatis, G. M. D., Demanze, S., Eisele, F., Fusani, L., Hock, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02136 · Cited by 25
Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention
Dias, M. H., & Bernards, R. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12979 · Cited by 22
Flemington, E. K., Flemington, S. A., O’Grady, T. M., Baddoo, M., Nguyen, T. T. T., Dong, Y., & Ungerleider, N. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad111 · Cited by 26
Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 24
Al-blewi, F. F., Alsehli, M., Hritani, Z. M., Eskandrani, A. A., Alsaedi, W. H., Alawad, M. O., Elhenawy, A. A., Ahmed, H. Y., El-Gaby, M. S. A., Afifi, T. H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316716 · Cited by 22
Gürbüz, F., Desai, S., Diao, F., Türkkahraman, D., Wranitz, F., Wood, M. A., Shin, Y. ‐., Kotan, L. D., Jiang, H., Witchel, S. F., et al. (2017) · Clinical Genetics · doi:10.1111/cge.13183 · Cited by 22
Ni, Y., Lin, W., Mu, R., Wu, C., Wang, L., Wu, D., Chen, S., & Pang, J. (2018) · RSC Advances · doi:10.1039/c8ra05600e · Cited by 22
Costanzo, A. D., Gaudio, N. D., Conte, L., & Altucci, L. (2020) · Cancers · doi:10.3390/cancers12071898 · Cited by 24
Structure driven compound optimization in targeted protein degradation
Leissing, T. M., Luh, L. M., & Cromm, P. M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.005 · Cited by 24
Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers
Şahin, İ., George, A., & Seyhan, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111790 · Cited by 23
DCAF16-Based Covalent Degradative Handles for the Modular Design of Degraders
Orr, L. M., Tomlinson, S. J., Grupe, H. R., Lim, M., Ho, E., Yilmaz, H., Zhou, G., Leon, B., Olzmann, J. A., & Nomura, D. K. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00959 · Cited by 23
Lü, J., Li, D., Jiang, H., Li, Y., Lu, C., Chen, T., Wang, Y., Wang, X., Sun, W., Pu, Z., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.103025 · Cited by 23
Jiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 23
Jia, X., Pan, L., Zhu, M., Hu, H., Zhai, L., Liu, J., Hu, M., Liu, B., & Tan, M. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103545 · Cited by 21
Chemical Modulation of Pre-mRNA Splicing in Mammalian Systems
Boer, R. E., Torrey, Z. R., & Schneekloth, J. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00001 · Cited by 21
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 22
Reprogramming RNA processing: an emerging therapeutic landscape
Neil, C. R., Seiler, M., Reynolds, D. J., Smith, J. J., Vaillancourt, F. H., Smith, P. G., & Agrawal, A. A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.02.011 · Cited by 23
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Development of CAPER peptides for the treatment of triple negative breast cancer
Chilewski, S. D., Bhosale, D., Dees, S., Hutchinson, I., Trimble, R. J., Pontiggia, L., Mercier, I., & Jasmin, J.-F. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1711579 · Cited by 21
Franco, A., Kumar, J., Lin, G., Behnamfar, N., Hsieh, L., Shimizu, C., Tremoulet, A. H., Burns, J. C., & Linden, J. M. (2017) · European Journal of Immunology · doi:10.1002/eji.201747139 · Cited by 20
Garber, K. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02164-9 · Cited by 22
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 25
Chu, Y., Chen, S., Yang, M., Chen, Y., Fang, H., Huang, P., Xie, Y., Sun, C., Chen, Y., Zhang, B., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02793-8 · Cited by 22
Self-citationSmall molecules modulating RNA splicing: a review of targets and future perspectives
Bouton, L., Ecoutin, A., Malard, F., & Campagne, S. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00685a · Cited by 21
Chang, X., Qu, F., Li, C., Zhang, J., Zhang, Y., Xie, Y., Fan, Z., Bian, J., Wang, J., Li, Z., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22024 · Cited by 22
Self-citationC646 degrades Exportin-1 to modulate p300 chromatin occupancy and function
Chen, Y., Rahman, A., Sax, J. L., Pleshinger, M. J. A., Friedrich, R. M., & Adams, D. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.05.016 · Cited by 22
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
Jin, Y., & Lee, Y. (2024) · ChemMedChem · doi:10.1002/cmdc.202400267 · Cited by 22
New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
Peng, W., Pan, X., Wang, S., Huang, G., & Qian, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03330 · Cited by 20
Systematic pan‐cancer analysis identifies RBM39 as an immunological and prognostic biomarker
Zhang, R., Wang, W., Zhang, N., Chen, X., Liu, W., Zhang, L., & Liu, N. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17517 · Cited by 19
Eléouët, M. P., Lu, C., Zhou, Y., Yang, P. X., Ma, J., & Xu, G. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194902 · Cited by 19
Naro, C., Antonioni, A., Medici, V., Caggiano, C., Jolly, A., de la Grange, P., Bielli, P., Paronetto, M. P., & Sette, C. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02986-0 · Cited by 20
Kohsaka, S., Yagishita, S., Shirai, Y., Matsuno, Y., Ueno, T., Kojima, S., Ikeuchi, H., Ikegami, M., Kitada, R., Yoshioka, K., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00610-0 · Cited by 24
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
Parker, G. S., Toth, J. I., Fish, S., Blanco, G., Kampert, T., Li, X., Yang, L., Stumpf, C. R., Steadman, K., Jamborcic, A., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0219 · Cited by 23
Discovery of a molecular glue for EGFR degradation
Wang, H., Wang, H., Wang, R., Li, Y., Wang, Z., Zhou, W., Deng, L., Li, X., Li, Z., Yang, Q., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03241-8 · Cited by 20
Alternative splicing: A key regulator in T cell response and cancer immunotherapy
Yong, C., Liang, Y., Wang, M., Jin, W., Fan, X., Wang, Z., Cao, K., Wu, T., Li, Q., & Chang, C. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107713 · Cited by 19
Olender, J., & Lee, N. H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-22254-3_10 · Cited by 22
Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
Pagliuca, S., Gurnari, C., & Visconte, V. (2021) · Cancers · doi:10.3390/cancers13040784 · Cited by 19
Lucas, E. L., Hewitt, K. A., Chen, P., Castro, A. J., Hong, X., & Jarvo, E. R. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02603 · Cited by 19
Pitolli, C., Marini, A., Guerra, M., Pieraccioli, M., Marabitti, V., Palluzzi, F., Giacò, L., Tamburrini, G., Cecconi, F., Nazio, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02790-2 · Cited by 19
DCAF15 control of cohesin dynamics sustains acute myeloid leukemia
Grothusen, G. P., Chang, R., Cao, Z., Zhou, N., Mittal, M., Datta, A., Wulfridge, P., Beer, T., Wang, B., Zheng, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49882-x · Cited by 17
Therapeutic approaches to treat human spliceosomal diseases
DeNicola, A. B., & Tang, Y. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.003 · Cited by 17
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 18
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Pan, Y., Wang, Y., & Gou, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108491 · Cited by 19
RNA splicing alterations in lung cancer pathogenesis and therapy
Yan, Y., Ren, Y., Bao, Y., & Wang, Y. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.04.004 · Cited by 16
Dou, Z., Lei, H., Su, W., Zhang, T., Chen, X., Yu, B., Zhen, X., Si, J., Sun, C., Zhang, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06507-x · Cited by 20
He, Y., Shao, Y., Zhou, Z., Li, T., Gao, Y., Liu, X., Yuan, G., Yang, G., Zhang, L., & Li, F. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06908-y · Cited by 17
Cullin-RING Ligase 4 in Cancer: Structure, Functions, and Mechanisms
Cheng, J., Bin, X., & Tang, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189169 · Cited by 20
Covalent targeting of splicing in T cells
Scott, K. A., Kojima, H., Ropek, N., Warren, C. D., Zhang, T. L., Hogg, S. J., Sanford, H., Webster, C. G., Zhang, X., Rahman, J. A., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.10.010 · Cited by 16
Molecular glue degrader for tumor treatment
Hu, Y., Yan, Y., Wang, J., Hou, J., & Lin, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1512666 · Cited by 19
In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)
Tomoshige, S., & Ishikawa, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116221 · Cited by 17
Szafrański, K., Slawinski, J. J., Tomorowicz, Ł., & Kawiak, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062235 · Cited by 16
Functional mapping of the 14-3-3 hub protein as a guide to design 14-3-3 molecular glues
Somsen, B. A., Craenmehr, F. W. B., Liu, W.-H. W., Koops, A. A., Pennings, M. A. M., Visser, E. J., Ottmann, C., Cossar, P. J., & Brunsveld, L. (2022) · Chemical Science · doi:10.1039/d2sc04662h · Cited by 15
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03130-8 · Cited by 17
Caggiano, C., Petrera, V., Ferri, M., Pieraccioli, M., Cesari, E., Leone, A. D., Sánchez, A. M., Fabi, A., Masetti, R., Naro, C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114751 · Cited by 15
Exploration of degrons and their ability to mediate targeted protein degradation
Harris, T. J., & Trader, D. J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00787e · Cited by 19
Engineering Forward Genetics into Cultured Cancer Cells for Chemical Target Identification
Povedano, J. M., Liou, J., Wei, D. H., Srivatsav, A., Kim, J., Xie, Y., Nijhawan, D., & McFadden, D. G. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.06.006 · Cited by 15
Self-citationTargeted Protein Degradation and Regulation with Molecular Glue: Past and Recent Discoveries
Fang, Y.-Z., He, Q., & Cao, J. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210806113949 · Cited by 16
The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress
Lemaitre, F., Chakrama, F. Z., O’Grady, T. M., Peulen, O., Rademaker, G., Deward, A., Chabot, B., Piette, J. G., Colige, A., Lambert, C. A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1130 · Cited by 16
Castaldi, M. P., Hendricks, J. A., & Zhang, A. X. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.03.003 · Cited by 15
The intricate dance of RNA-binding proteins: unveiling the mechanisms behind male infertility
Gao, Y. J., Zhou, Y., Hong, Z., Ma, B., Wang, X., Nie, L., Ma, L., Zhang, Y., Zhang, M., & Wang, M. (2025) · Human Reproduction Update · doi:10.1093/humupd/dmaf023 · Cited by 12
Targeted protein degradation technologies: Emerging mechanisms and nano-based innovations
Hou, M., Zhao, R., Wang, S., Jiang, B., & Yan, X. (2025) · Nano Research · doi:10.26599/nr.2025.94907983 · Cited by 15
Targeting RNA-binding proteins with small molecules: perspectives and challenges
Konde, O. M., Balela, W. B., & Tshitenge, T. B. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1649692 · Cited by 14
Lu, C., Cai, Y., Wu, S., Wang, Y., Li, J., Xu, G., & Ma, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107751 · Cited by 15
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
Singh, S. V., Fang, J., Jin, H., de Velde, L.-A. V., Cortes, A., Chen, J., Natarajan, S., Poon, E., Wu, Q., Morton, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63979-x · Cited by 16
Pogacar, Z., Johnson, J. L., Krenning, L., De Conti, G., Jochems, F., Lieftink, C., Velds, A., Wardak, L., Groot, K., Schepers, A., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0273182 · Cited by 13
Small molecule inhibition of RNA binding proteins in haematologic cancer
Jaiswal, A. K., Thaxton, M. L., Scherer, G., Sorrentino, J. P., Garg, N. K., & Rao, D. S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2303558 · Cited by 16
Identification of novel GSPT1 degraders by virtual screening and bioassay
Zhang, S., Nie, S., Ma, G., Shen, M., Kong, L., Zuo, Z., & Li, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116524 · Cited by 16
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.